Abstract: Amide and urea derivatives of the formula I

Abstract: Benzofurane derivatives of formula (I), wherein R and R′ have the meanings given in claim no. (1), and salts thereof are suitable for use as intermediate products in the synthesis of medicaments.

Abstract: Amide and urea derivatives of the formula I R1—(CH2)n—(Y)q—(Z)r—CO—NH—R2  (I) in which R1, n, Y, q, Z, r and R2 have the meanings indicated in Claim 1, are potent 5-HT1B/1D antagonists and exhibit 5-HT reuptake-inhibiting actions and are suitable for the treatment and prophylaxis of anxiety states, depressions, schizophrenia, compulsive ideas, tardive dyskinesias, learning disorders, age-dependent memory disorders, for positively affecting obsessive-compulsive behaviour (OCD), and also for the treatment and for the control of the sequelae of cerebral infarcts such as stroke and cerebral ischaemias.

Abstract: The invention relates to novel oxazolidine derivatives of the formula in which R1, R2 and R3 have the meanings stated in claim 1, their salts and processes for preparing the compounds according to the invention. The compounds of the formula I act as 5-HT2A antagonists with a 5-HT reuptake-inhibiting, antidepressant or anxiolytic effect and can be used to produce pharmaceuticals.

Abstract: The present invention relates to sulphonylexazolamines of general formula (I), wherein R1, R2 represent independently from each other H, A, —(CH2)n—Ar or alkenyl with 2-6 C atoms, R1 and R2 together also represent a mononuclear saturated heterocycle with 1-2 N, O and/or S atoms, Z is H, A, CF3, NO2, Hal, OH, OA, NH2, NHA or NH2. A represents alkyl with 1-6 C atoms, Ar is Z-monosubstituted or Z-disubstituted phenyl, Hal is F, Cl, Br, or L n is 1 or 2 of the physiologically acceptable salts or solvates thereof. Said sulphonyloxazolamines are used as therapeutic active ingredients. The invention also relates to the use of sulphonyloxazolamines as therapeutic active ingredients and/or to the production of pharmaceutical preparations to combat diseases of the central nervous system. The invention further relates to a pharmaceutical preparation and the production thereof.

Abstract: The invention relates to piperidine derivatives of the formula I in which R1, R2, m and k have the meanings indicated in claim 1, and their salts, novel intermediates and processes for the preparation of the compounds according to the invention. The compounds of the formula I are potent a receptor ligands and show 5-HT reuptake-inhibiting actions and can be used for the production of medicaments, for example for the treatment of disorders of the central nervous system, of strokes, brain or bone marrow traumata or of ischaemic states.

Abstract: Compound of the formula I in which Q and Ar have the meanings indicated herein, and their salts, exhibit actions on the central nervous system.

Abstract: Piperazine derivatives of the formula I in which R1, m, k and R2 have the meanings indicated in claim 1, are potent 5-HT1A agonists and exhibit 5-HT-reuptake-inhibiting actions and are suitable for the treatment and prophylaxis of anxiety states, depression, schizophrenia, obsessions, tardive dyskinesias, learning disorders, age-dependent memory disorders, for positively affecting obsessive-compulsive disorder, and also for the treatment and for the control of the sequelae of cerebral infarcts such as stroke and cerebral ischaemias.

Abstract: Piperazinylbenzodioxane derivatives of formula I ##STR1## wherein B is an indol-3-yl or benzimidazol-1-yl radical which is unsubstituted or monosubstituted by CN, CO--R.sup.1, C.sub.n H.sub.2n --R.sup.1, Hal, OH, OA, O--C.sub.n H.sub.2n --CO--R.sup.1, or NHR.sup.2, and Q is C.sub.n H.sub.2n, or a physiologically acceptable salt thereof. The derivatives are active in the central nervous system, especially as serotonin agonists and antagonists.